1. Introduction {#sec1-marinedrugs-16-00474}
===============

Marine organisms have always been an attractive source of natural products with novel and exotic structures and useful biological activities \[[@B1-marinedrugs-16-00474],[@B2-marinedrugs-16-00474],[@B3-marinedrugs-16-00474],[@B4-marinedrugs-16-00474],[@B5-marinedrugs-16-00474],[@B6-marinedrugs-16-00474],[@B7-marinedrugs-16-00474],[@B8-marinedrugs-16-00474],[@B9-marinedrugs-16-00474],[@B10-marinedrugs-16-00474],[@B11-marinedrugs-16-00474]\]. Marine sponges of the genus *Hyrtios* (order Dictyoceratida family Thorectidae) have yielded scalarane \[[@B6-marinedrugs-16-00474],[@B8-marinedrugs-16-00474],[@B12-marinedrugs-16-00474],[@B13-marinedrugs-16-00474],[@B14-marinedrugs-16-00474]\] and manoalide \[[@B12-marinedrugs-16-00474]\] types sesterterpenes, which are important groups of active secondary metabolites. They have been reported to possess many biological activities, such as cytotoxic \[[@B3-marinedrugs-16-00474],[@B6-marinedrugs-16-00474],[@B15-marinedrugs-16-00474],[@B16-marinedrugs-16-00474]\], antibacterial \[[@B9-marinedrugs-16-00474],[@B11-marinedrugs-16-00474]\], antibiotic \[[@B17-marinedrugs-16-00474]\] activities, inhibition of the DNA-relaxing activity of mouse DNA topoisomerase I \[[@B12-marinedrugs-16-00474]\], and enhancement nerve growth factor synthesis in cultured astroglial cells \[[@B13-marinedrugs-16-00474]\]. As a part of our ongoing research program focused on the discovery of cytotoxic compounds from Thai marine sponges \[[@B18-marinedrugs-16-00474],[@B19-marinedrugs-16-00474],[@B20-marinedrugs-16-00474]\], drawing from the previous report, one sesterterpene, erectusolide A, six phenolic alkenes, erectuseneols A--F, together with nine known compounds, were isolated from the EtOAc soluble extract of *Hyrtios erectus* (Chulabhorn Research Institute (CRI) 588) \[[@B3-marinedrugs-16-00474]\]. Of these, some sesterterpenes exhibited significant cytotoxic activities against the MOLT-3 cell line with an IC~50~ values of 3.79--5.82 μM \[[@B3-marinedrugs-16-00474]\]. Accordingly, further investigation of the EtOAc soluble extract was carried out, leading to the isolation of four new sesterterpenes, erectusolides B (**1**), C (**2**), D (**4**), and seco-manoalide-25-methyl ether (**3**), two new 2-furanone derivatives, erectusfuranones A and B (**5** and **6**), together with seventeen known sesterterpenes, which were identified as (6*Z*)-neomanoalide-24-acetate (**7**) \[[@B9-marinedrugs-16-00474]\], two diastereomers of 24-*O*-methylmanoalide (**8** and **9**) \[[@B10-marinedrugs-16-00474]\], luffariolide B (**10**) \[[@B15-marinedrugs-16-00474]\], manoalide (**11**) \[[@B10-marinedrugs-16-00474],[@B12-marinedrugs-16-00474],[@B17-marinedrugs-16-00474]\], (6*E*)- and (6*Z*)-neomanoalides (**12** and **13**) \[[@B12-marinedrugs-16-00474],[@B15-marinedrugs-16-00474],[@B17-marinedrugs-16-00474]\], seco-manoalide (**14**) \[[@B12-marinedrugs-16-00474],[@B17-marinedrugs-16-00474]\] scalarafuran (**15**) \[[@B8-marinedrugs-16-00474],[@B16-marinedrugs-16-00474]\], 12-acetylscalarolide (**17**) \[[@B21-marinedrugs-16-00474]\], 12-epi-*O*-deacetyl-19-deoxyscalarin (**18**) \[[@B8-marinedrugs-16-00474],[@B16-marinedrugs-16-00474]\], 12-epi-scalarin (**19**) \[[@B13-marinedrugs-16-00474],[@B16-marinedrugs-16-00474]\], and 12-*O*-deacetyl-12-epi-scalarin (**20**) \[[@B13-marinedrugs-16-00474],[@B14-marinedrugs-16-00474],[@B16-marinedrugs-16-00474]\], three indole alkaloids, 5-hydroxy-1*H*-indole- 3-carbaldehyde (**21**) \[[@B14-marinedrugs-16-00474],[@B22-marinedrugs-16-00474]\], hyrtiosine A (**22**) \[[@B14-marinedrugs-16-00474],[@B22-marinedrugs-16-00474]\], and variabine B (**23**) \[[@B7-marinedrugs-16-00474]\], and one norterpene, cavernosine (**16**) \[[@B3-marinedrugs-16-00474],[@B23-marinedrugs-16-00474]\]. All of the known compounds ([Figure 1](#marinedrugs-16-00474-f001){ref-type="fig"}) were readily identified by extensive study of their spectral data, including high resolution atmospheric pressure chemical ionization mass spectrometry (HRAPCIMS) or high resolution electrospray ionization mass spectrometry (HRESIMS), 1D and 2D nuclear magnetic resonance (NMR) data, as well as by comparison with those reported in the literatures.

2. Results {#sec2-marinedrugs-16-00474}
==========

Two separate collections of *H. erectus* were studied; and they were collected in February 2011 from different locations of the Similan Island, Phangnga province, Thailand. The MeOH extract of the Thai marine sponge *H. erectus* from collection CRI 588 was dissolved in H~2~O and partitioned with EtOAc. The EtOAc soluble extract was fractionated by column chromatography over silica gel, Sephadex LH-20, and reversed-phase high performance liquid chromatography (HPLC) to afford three new sesterterpenes, erectusolides B (**1**), C (**2**), and seco-manoalide-25-methyl ether (**3**), two new 2-furanone derivatives, erectusfuranones A (**5**) and B (**6**) together with eight known sesterterpenes, **7**--**14**. One additional new sesterterpene, erectusolide D (**4**), and ten known compounds (**13**, **15**--**23**) were obtained from the *H. erectus* collection CRI 572. All new compounds showed considerable structural similarity with the co-occurring known sesterterpenes.

Compound **1** was obtained as a weak optical rotation value ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −1.3), and its molecular formula was determined to be C~25~H~36~O~3~ (eight degrees of unsaturation) by HRAPCIMS. Infrared (IR) absorption bands of compound **1** suggested the presence of *β*-substituted *α*,*β*-unsaturated *γ*-lactone (*β*-substituted butenolide) at 1779 and 1746 cm^−1^ and hydroxyl group at 3443 cm^−1^. Four of the eight degrees of unsaturation implied by the molecular formula of **1** were taken up in one carbon--oxygen double bonds and three carbon--carbon double bonds, thus indicating the tetracyclic nature of the molecule. The ^13^C and (distortionless enhancement by polarization transfer (DEPT) NMR spectra of **1** showed 25 carbons including, 4 tertiary methyls, 7 methylenes, 2 oxymethylenes, 3 methines, 2 olefinic methines, and 7 quaternary carbons. The ^1^H and ^13^C NMR spectral data of **1** ([Table 1](#marinedrugs-16-00474-t001){ref-type="table"}, [Figures S1 and S2](#app1-marinedrugs-16-00474){ref-type="app"}) were comparable to those of luffariolides A ([Figure 1](#marinedrugs-16-00474-f001){ref-type="fig"}) and B (**10**) and implied that all compounds possessed identical two terminal units, which included a polyalkylated-cyclohexene (C~12~--C~22~) and *β*-substituted butenolide moieties. The major differences were found in the C~4~--C~11~, and C-23. In the ^1^H--^1^H COSY correlation of **1** ([Figure 2](#marinedrugs-16-00474-f002){ref-type="fig"}), H-6 (δ~H~ 5.67) showed allylic coupling to H~ax~-8 (1H, δ~H~ 1.90--2.00) and H~2~-24 (2H, δ~H~ 4.03/4.06) and H-5 was coupled to H-4, H-6, and H-10. From its ^1^H--^1^H correlation spectroscopy (COSY) spectrum of **1** ([Figure 2](#marinedrugs-16-00474-f002){ref-type="fig"}), typical allylic coupling of the olefinic methines at δ~H~ 5.86 (H-2) and 5.67 (H-6) with the respective methine signal at δ~H~ 2.74 (H-4) and oxymethylene at δ~H~ 4.03/4.06 (H~2~-24) were discernable. Both the COSY and heteronuclear multiple bond correlation (HMBC) data indicated that the double bonds were not conjugated to each other. The ^1^H, ^13^C, and COSY NMR data confirmed the presence of a 3-hydroxymethylbicyclo \[4.2.0\] oct-2-ene (C~4~--C~11~ and C-24) in the molecule. The HMBC correlations of **1** ([Figure 2](#marinedrugs-16-00474-f002){ref-type="fig"} and [Figure S4](#app1-marinedrugs-16-00474){ref-type="app"}), the proton signal at δ~H~ 5.86 (H-2) correlated to methine carbon at δ~C~ 51.0 (C-4), H-4 at δ~H~ 2.74 correlated to quaternary carbon at δ~C~ 169.7 (C-3), methine carbon at δ~C~ 115.3 (C-2), and methylene carbon at δ~C~ 73.2 (C-25) allowed the connectivity of the butenolide with the bicyclic ring through the linkage of C-3 and C-4. The linkage of the polyalkylated-cyclohexene and CH~3~-23 at quaternary C-11 on the molecule were deduced from the HMBC correlations of H~3~-23 (δ~H~ 1.13) with C-4, C-10 (δ 37.0), C-11 (δ 43.0), and C-12 (δ 36.6) and the correlations of H~2~-12 (δ~H~ 1.28--1.36 and 1.58--1.66) with C-4, C-10, C-14 (δ 136.3), and C-23 (δ 21.5). The large trans-diaxial coupling constant between H~ax~-9 and H~ax~-10 (*J* = 12.2 Hz) on the cyclohexene ring suggested the *β*-configuration of H~ax~-10. The relative stereochemistry of **1** was established by analysis of the (nuclear overhauser effect spectroscopy (NOESY) spectrum (in CDCl~3~ and C~6~D~6~; [Figure 2](#marinedrugs-16-00474-f002){ref-type="fig"}). NOESY cross-peaks resonance of H-4, H~α~-9, and H~3~-23 and H-5, H-10, H-12, and H-2 implied a *cis*-junction for rings B/C and H-5, H~ax~-10, *β*-substituted butenolide moiety, and polyalkylated-cyclohexene (C~12~--C~22~) are on the same face while the methyl group (CH~3~-23) and H-4 on the opposite face of the molecule. Structure **1** with relative stereochemistry as shown was thus assigned to erectusolide B, which contained fused cyclohexene and cyclobutane rings. It could derive from luffariolide A ([Figure 1](#marinedrugs-16-00474-f001){ref-type="fig"}) \[[@B11-marinedrugs-16-00474]\], through a biogenetic pathway involving a 2 + 2 cycloaddition of double bonds at C-4/C-5 and C-10/C-11 as suggested by Lin, H.W. and co-workers \[[@B4-marinedrugs-16-00474]\]. Furthermore, compounds **1** and **2** represent two important compounds which lend further support for the proposed biosynthetic pathway of Lin et. al. for the cyclobutane formation \[[@B4-marinedrugs-16-00474]\]. This substance has an optical rotation near zero ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −1.3); attempting to separate the substance using various chiral columns was found to be inseparable.

Compound **2** was obtained as optically active ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −18.5), and its molecular formula was determined to be C~25~H~34~O~3~ (nine degrees of unsaturation) by HRAPCIMS. Infrared (IR) absorption bands of compound **2** suggested the presence of *β*-substituted *α*,*β*-unsaturated *γ*-lactone at 1779 and 1746 cm^−1^ and *α*,*β*-unsaturated carbonyl group at 1682 cm^−1^. The ^1^H and ^13^C NMR spectroscopic data of **2** ([Table 1](#marinedrugs-16-00474-t001){ref-type="table"}, [Figures S4--S8](#app1-marinedrugs-16-00474){ref-type="app"}) indicated that it was essentially identical to compound **1**, except for the presence of an aldehyde group (δ~H~ 9.45, s; δ~C~ 192.9) for **2** in place of the hydroxylmethyl group (δ~H~ 4.03/4.06, each d, *J* = 13.2 Hz, δ~C~ 66.8) for **1**. This was further confirmed by the HMBC correlations ([Figures S11 and S12](#app1-marinedrugs-16-00474){ref-type="app"}) between olefinic H-6 (δ~H~ 6.74) and aldehydic carbon (δ~C~ 192.9) and between proton aldehyde (δ~H~ 9.45) and C-7 (δ~C~ 143.7) and C-8 (δ~C~ 19.4). The NOESY spectrum of **2** was similar to that observed of **1** indicating the same relative stereochemistry. Thus, compound **2** was suggested to be the formaldehyde analog of **1**, and named erectusolide C. This compound has low optical rotation ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −18.5); attempting to separate the compound using various chiral columns was unsuccessful.

Compound **3** was obtained as a pale yellow solid, exhibiting similar ultraviolet (UV), infrared (IR), ^1^H, and ^13^C NMR spectra ([Table 2](#marinedrugs-16-00474-t002){ref-type="table"}, [Figures S13 and S14](#app1-marinedrugs-16-00474){ref-type="app"}) as (6*E*) seco-manoalide (**14**) \[[@B17-marinedrugs-16-00474]\]. Accurate mass measurement by HRAPCIMS of **3** indicated a pseudo molecular ion peak at *m/z* 465.2414 \[M + Cl\]^−^ (calcd for C~26~H~38~ClO~5~, 465.2413), consistent with the molecular formula C~26~H~38~O~5~. This difference of 14 amu compared to the molecular formula of **14**, and the appearance of a signal of methoxy group in ^1^H, and ^13^C NMR spectra of **3** at δ~H~ 3.65 and δ~C~ 57.9. It is suggested that the hydroxyl group at C-25 was replaced by a methoxyl group. This was further confirmed by the HMBC correlations ([Figure S16](#app1-marinedrugs-16-00474){ref-type="app"}) between the methoxyl protons (δ~H~ 3.65) and hemiacetal carbon (δ~C~ 103.3) and between H-25 (δ~H~ 5.84) and methoxyl carbon (δ~C~ 57.9). The absolute stereochemistry at C-4 of **3** was determined by the modified Mosher's method \[[@B24-marinedrugs-16-00474]\]. The hydroxyl group of **3** was converted into both the *S*- and *R*-MTPA esters **3a** and **3b**, respectively. The ^1^H NMR chemical shifts were assigned by the analysis of the ^1^H--^1^H COSY NMR data for each MTPA ester (experimental section). The calculated Δδ*~S~*~−*R*~ values were positive for the H~2~-5 (+0.03 and +0.03), H-6 (+0.15), H~2~-8 (+0.04), and H-24 (+0.11) and negative for the H-2 (−0.13), 25-OMe (−0.004), and H-25 (−0.02) ([Figure 3](#marinedrugs-16-00474-f003){ref-type="fig"}), implying that the absolute configuration of C-4 was *R*. Thus, compound **3** was characterized as (4*R*,6*E*) seco-manoalide-25-methyl ether.

Compound **4** was obtained as an optically active ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −20.9), and its molecular formula was determined to be C~25~H~38~O~5~ (seven degrees of unsaturation) by HRAPCIMS. Five of the seven degrees of unsaturation implied by the molecular formula of **4** were taken up in one carbon--oxygen double bonds and four carbon--carbon double bonds, thus indicating the bicyclic nature of the molecule. The IR spectrum exhibited absorption bands corresponding to a hydroxyl group (3424 cm^−1^), an ester carbonyl (1739 cm^−1^), and an exomethylene substituent (898 cm^−1^). Similarities in the NMR spectra between compounds **4** ([Table 2](#marinedrugs-16-00474-t002){ref-type="table"}, [Figures S17 and S18](#app1-marinedrugs-16-00474){ref-type="app"}) and 6*Z*-neomanoalide (**13**) suggested that compound **4** was also a neomanoalide-type sesterterpene \[[@B17-marinedrugs-16-00474]\].

The main differences in the ^1^H NMR spectra of **4** and compound **13** were the absence of one olefinic methyl group resonance in compound **4** and the appearance of a resonance attributable to an exomethylene moiety (δ~H~ 4.83 and 4.91, H~2~-22). Observation of a sp^2^ methylene carbon resonance (δ~C~ 108.3) and a corresponding quaternary carbon (δ~C~ 150.5) further supported the presence of a exocyclic methylene functionality in the structure of **4**. An oxygenated quaternary carbon (δ~C~ 80.4, C-14) was observed by ^13^C NMR and DEPT experiments. The assignment and placement of the hydroxyl substituent at C-14 and the exocyclic methylene at C-15 were deduced by observation of long range ^1^H--^13^C HMBC correlations ([Figure 4](#marinedrugs-16-00474-f004){ref-type="fig"} and [Figure S20](#app1-marinedrugs-16-00474){ref-type="app"}) (H~2~-13, H~2~-16, H~2~-18, H~3~-21/22 to C-14, H~2~-17 to C-15, and H~2~-16 to C-22). The relative stereochemistry of the methylenecyclohexane unit was elucidated mainly on the basis of NOESY correlations ([Figure 4](#marinedrugs-16-00474-f004){ref-type="fig"}). The correlations among axial H~α~-18 (δ~H~ 1.63, td, *J* = 13.0, 5.7 Hz), axial methylene H~2~-13, and equatorial CH~3~-20 (δ~H~ 0.96) and correlations among axial H~3~-21 (δ~H~ 0.88), exocyclic methylene H~2~-22, and equatorial H~β~-18 (δ~H~ 1.37, brd, *J* = 13.7 Hz) that were observed in **4** indicated that the equatorial hydroxyl group at C-14 occupied the *β*-face. The geometry of the olifinic bonds was assigned as 6*Z*,10*E* on the basis of NOESY correlations between H~2~-5 and H~2~-24 and between H~2~-9 and H~3~-23, respectively. Compound **4** exhibited a negative optical rotation {$\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −20.9 (*c* 1.64, CHCl~3~)}, similar to that of 6*Z*-neomanoalide (**13**) {$\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −28 (*c* 0.8, CH~2~Cl~2~)} \[[@B12-marinedrugs-16-00474]\] the relative stereochemistry at C-4 of **4** was then assigned to be *R*. Thus, the structure **4** was concluded as shown in [Figure 1](#marinedrugs-16-00474-f001){ref-type="fig"} and was named erectusolide D.

Compound **5** was obtained as optically active ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +1.3), and its molecular formula was determined to be C~23~H~42~O~3~ (three degrees of unsaturation) by HRESIMS. The IR absorption bands data of compound **5** suggested the presence of *β*-substituted *α*, *β*-unsaturated *γ*-lactone (*β*-substituted butenolide for three degrees of unsaturation in the structure at 1777 and 1739 cm^−1^ in addition to the hydroxyl group at 3442 cm^−1^. The ^1^H and ^13^C NMR spectra of **5** as shown in [Table 3](#marinedrugs-16-00474-t003){ref-type="table"} ([Figures S11 and S22](#app1-marinedrugs-16-00474){ref-type="app"}) suggests that compound **5** possess *β*-substituted butenolide moiety to which a saturated long chain hydrocarbon group is attached. The ^1^H NMR signals at δ~H~ 5.93 (1H) and 4.85 (2H) assignable to an olefinic proton and methylene protons at the *α*- and *γ*-positions of the *α*,*β*-unsaturated *γ*-lactone, respectively, reveals that the long chain hydrocarbon group is attached at the *β*-position (C-4). The 2-hydroxy-16-methyloctadecane group (long chain hydrocarbon) was assigned by a combination of HRESIMS, ^1^H and ^13^C NMR, DEPT, COSY, HSQC ([Figure S23](#app1-marinedrugs-16-00474){ref-type="app"}), and HMBC analyses. The HMBC spectrum of **5** ([Figure 5](#marinedrugs-16-00474-f005){ref-type="fig"} and [Figure S24](#app1-marinedrugs-16-00474){ref-type="app"}) showed the correlations from two of the methyl protons at δ~H~ 0.85 (H~3~-18′, t, *J* = 7.2 Hz) and δ~H~ 0.84 (H~3~-19′, d, *J* = 6.0 Hz) to the methine carbon at δ~C~ 34.4 (C-16′) and methylene carbon at δ~C~ 29.42 (C-17′) suggesting that the position of the second methyl group was attached at C-16′. In the HMBC spectrum of **5** also showed the correlations between methylene H~2~-1′ (δ~H~ 2.52/2.64) and C-3 (δ~C~ 117.3), C-2′ (δ~C~ 70.2), C-3′ (δ~C~ 37.7), and C-5 (δ~C~ 73.8) and between H-2′ (δ~H~ 3.84--3.90) and C-4 (δ~C~ 167.3), C-4′ (δ~C~ 25.5) indicating clearly that the methylene carbon (C-1′) of 2-hydroxy-16-methyloctadecyl attached to the C-4 of the *α*,*β*-unsaturated *γ*-lactone. The absolute stereochemistry at C-2′ of **5** was determined by the modified Mosher's method \[[@B24-marinedrugs-16-00474]\]. The hydroxyl group of **5** was converted into both the *S*- and *R*-MTPA esters **5a** and **5b**, respectively, each of which was a single diastereoisomer by ^1^H and COSY NMR experiments. The calculated Δδ*~S~*~-*R*~ values were positive for the H~2~-3′ (+0.04) and H~2~-4′ (+0.06), while Δδ*~S~*~-*R*~ values were negative for H~2~-1′ (−0.07 and −0.06), H-3 (−0.09), and H~2~-5 (−0.13 and −0.27) ([Figure 6](#marinedrugs-16-00474-f006){ref-type="fig"}), which implied the absolute configuration of C-2′ was *R*. Thus, compound **5** was characterized as 4-((2*R*)-2-hydroxy-16-methyloctadecyl)furan-2(5*H*)-one and was named erectusfuranone A.

Compound **6** was obtained as optically active ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −4.9), and its molecular formula was determined to be C~22~H~40~O~3~ (three degrees of unsaturation) by HRESIMS. The UV, IR, ^1^H and ^13^C NMR ([Figures S25 and S26](#app1-marinedrugs-16-00474){ref-type="app"}) spectroscopic data of **6** indicated that it was essentially identical to compound **5**. The signals of a methine moiety (C-16′; δ~C~ 34.3, δ~H~ 1.23--1.37) and a methyl group (C-19′; δ~C~ 19.2, δ~H~ 0.84) were not evident in **6**, instead a methylene group (C-16′; δ~C~ 31.9, δ~H~ 1.22--1.31) was observed. The absolute stereochemistry at C-2′ of **6** was determined by the modified Mosher's method \[[@B24-marinedrugs-16-00474]\]. The hydroxyl group of **6** was converted into both the *S*- and *R*-MTPA esters **6a** and **6b**, respectively, each of which was a single diastereoisomer judged by ^1^H and COSY NMR experiments. The Δδ*~S~*~-*R*~ ([Figure 6](#marinedrugs-16-00474-f006){ref-type="fig"}) values observed in the ^1^H NMR spectra were calculated and the resulting positive Δδ values for H~2~-6 (+0.04 and +0.04) and H~2~-7 (+0.06), and negative Δδ values for H~2~-1′ (−0.06 and −0.06), H-3 (−0.09), and H~2~-5 (−0.12 and −0.26) were consistent with the 2′*R* configuration. Thus, compound **6** was characterized as (*R*)-4-(2-hydroxyoctadecyl) furan-2(5*H*)-one and was named erectusfuranone B.

Cytotoxicity of the isolated compounds **3**, **5**, **7**--**20** and **23** were evaluated against several cancer cell lines such as ([Table 4](#marinedrugs-16-00474-t004){ref-type="table"}), MOLT-3 (acute lymphoblastic leukemia), HepG2 (hepatocarcinoma), HeLa (human cervical carcinoma), HuCCA-1 (human chlolangiocarcinoma), A549 (non-small-cell lung cancer), H69AR (multidrug resistance small-cell lung cancer), KB (human epidermoid carcinoma in the mouth), T47D (hormone dependent breast cancer), MDA-MB-231 (hormone independent breast cancer), and MRC-5 (normal embryonic lung cell). Compounds **8**, **9**, **14** and **20** showed good cytotoxic activity against MOLT-3 cell line with IC~50~ values of 1.77, 1.30, 6.68, and 7.64 μM, respectively, compounds **8** and **9** also showed cytotoxic activity against HeLa, HuCCA-1, and A549 cell lines with IC~50~ values of 1.51--16.77 μM. In addition, compounds **8** and **20** selectively exhibited cytotoxic activity toward the MOLT-3 (IC~50~ 1.77 and 7.64 µM, respectively) cancer cell line with the selectivity index (SI) value of 7 (IC~50~ 13.00 µM for normal cell line, MRC-5) and 9 (IC~50~ 70.97 µM for MRC-5), respectively. The SI value is the ratio of IC~50~ of normal cell (MRC-5) and IC~50~ of cancer cell line. Compound **9** selectively exhibited cytotoxic activity against MOLT-3 (IC~50~ 1.30 µM) and HeLa (IC~50~ 1.51 µM) cell lines with respective SI values of 8 and 7 (IC~50~ 10.84 µM for MRC-5). Manoalides **8** and **9**, the acetal derivatives of the hemiacetal **11**, showed higher activity than **11**, suggesting that the presence of 24-*O*-methyl of manoalides **8** and **9** were important for cytotoxic activity ([Table 4](#marinedrugs-16-00474-t004){ref-type="table"}). Manoalide **11** was previously reported to possess good cytotoxicity against L1210 (mouse lymphocytic leukemia) and KB (mouth epidermal carcinoma) cell lines with the IC~50~ value of 0.053 and 0.63 µM, respectively \[[@B12-marinedrugs-16-00474]\]. Compound **20** (12-*O*-deacetyl-12-epi-scalarin) exhibited cytotoxic activity against A549 cells with an IC~50~ of 73.38 µM ([Table 4](#marinedrugs-16-00474-t004){ref-type="table"}), while its IC~50~ have been reported in the literature to be 36.82 μM \[[@B16-marinedrugs-16-00474]\]. Luffariolide B (**10**), (6*E*)- and (6*Z*)-neomanoalides (**12** and **13**) showed weak cytotoxicity against the MOLT-3 cell line with IC~50~ of 35.45, 37.81, and 34.10 μM, respectively, but they exhibited cytotoxicity against the L1210 cell line with IC~50~ of 3.23, 24.38, and 13.93 μM, respectively \[[@B15-marinedrugs-16-00474]\].

3. Experimental Section {#sec3-marinedrugs-16-00474}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00474}
------------------------------------

Optical rotations were recorded on a JASCO DIP 1020 polarimeter using cylindrical glass cell (10 mm inner diameter (I.D.) × 10 mm). UV spectra were measured with a UV-1700 Pharma Spec (Shimadzu, Kyoto, Japan) spectrophotometer. Fourier transform infrared (FTIR) spectra were obtained using a universal attenuated total reflectance attached on Perkin Elmer Spectrum One spectrometer (PerkinElmer, Waltham, MA, USA). Nuclear magnetic resonance (NMR) spectra were recorded in a CDCl~3~ or C~6~D~6~ solution containing Me~4~Si as internal standard on Bruker AM400 or AVANCE600 spectrometer (Bruker Corporation, Billerica, MA, USA). HR--MS was performed on a Bruker (Micro ToF, Bruker Corporation, Billerica, MA, USA) spectrometer. HPLC was carried out on a Waters 600 system (Warers Corporation, Milford, MA, USA) equipped with a Waters Delta 600 pump, a Waters 600 Controller, a Waters 2998 photodiode array detector, and Waters Empower 2 software. Sephadex^™^ LH-20 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) was used for a column gel filtration. All commercial grade solvents were distilled prior to use and spectral grade solvents were used for spectroscopic measurements.

3.2. Sponge Material {#sec3dot2-marinedrugs-16-00474}
--------------------

Sponges (*Hyrtios erectus*) CRI 572 and CRI 588 were collected by hand using scuba at a depth of 30--40 feet in the Similan Island at the Andaman Sea (Phangnga province, Thailand) on 22 and 23 February 2011, respectively. The sponges were identified by Dr. Sumaitt Putchakarn, Head of Marine Biodiversity Research, Unit Curator of Porifera and Echinodermata, Institute of Marine Science, Burapha University, Bangsaen, Chonburi, Thailand. The voucher specimens (CRI 572 and CRI 588) were presently deposited at the Laboratory of Natural Products, Chulabhorn Research Institute, Bangkok, Thailand.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-16-00474}
-----------------------------

A frozen sample (2.6 kg) of *H. erectus* collection CRI 572 was cut into small pieces and extracted exhaustively with MeOH. The extract was filtered through cotton, and then evaporated under reduced pressure to give an aqueous residue, which was partitioned with EtOAc. The organic layer was concentrated to give a dark brown solid (7.52 g). The EtOAc--soluble fraction was subjected to vacuum liquid chromatography on silica gel and eluted with an EtOAc--hexane gradient (0→100% of EtOAc). Nine fractions (F1--F9) were obtained. F2 (340.5 mg) was subjected to column chromatography on Sephadex LH-20, using CH~2~Cl~2~--MeOH (1:1) to give compound **15** (16 mg). F4 (293.3 mg) was repeatedly fractionated by Sephadex LH-20, using CH~2~Cl~2~--MeOH (1:1) to give a mixture compounds (96.8 mg) that was separated using on a HPLC column (Hichrome C18, 5 µm, 21.2 mm × 250 mm with MeOH--H~2~O (gradient, 77→97% MeOH for 40 min), flowrate 12 mL/min, λ 220, 265 nm) to afford compounds **16** (28 mg, at 12.7 min), **17** (4.9 mg, at 32.5 min). F5 (574.4 mg) was subjected to column chromatography on Sephadex LH-20, using 100% MeOH to obtain a mixtures compound (9.3 mg) that was separated using on a HPLC column (Sunfire C18, 5 µm, 10 mm × 250 mm, with 80% CH~3~CN--H~2~O, flowrate 3 mL/min, λ 220 nm) to afford **18** (4.0 mg, at 25.7 min). F6 (976.4 mg) was subjected to column chromatography on Sephadex LH-20, using CH~2~Cl~2~--MeOH (1:1) to give three fractions (f1--f3). Fraction f1 was subjected to repeated chromatography on Sephadex LH-20, using 100% MeOH to give a mixtures compound (73.5 mg) that was separated using a HPLC column (Hichrome C18, 5 µm, 21.2 mm × 250 mm, with MeOH--H~2~O (gradient, 75→100% MeOH for 50 min), flowrate 12 mL/min, λ 220 nm) to afford compound **19** (2.3 mg, at 35.2 min). Fraction f2 was subjected to column chromatography on Sephadex LH-20, using 100% MeOH to give a mixtures compound (45.6 mg) that was separated using on a HPLC column (Sunfire C18, 5 µm, 19 mm × 250 mm, with 88% MeOH--H~2~O, flowrate 12 mL/min, λ 220 nm) to afford **20** (20 mg, at 16.7 min). Fraction f3 was subjected to repeated chromatography on Sephadex LH-20, using 100% MeOH to give a mixtures compound (6.9 mg) that was separated using on a preparative thin layer chromatography (PTLC) \[hexane--CH~2~Cl~2~--acetone (2:2:1) as eluent\] to afford **21** (1.4 mg). F7 (508.1 mg) was subjected to column chromatography on Sephadex LH-20, using 100% MeOH to give a mixtures compound (12.1 mg) that was separated using on a HPLC column (Sunfire C18, 5 µm, 19 mm × 250 mm, with 20% MeOH--H~2~O, flowrate 12 mL/min, λ 254 nm) to afford compound **22** (7.5 mg, at 12.8 min). F8 (298.1 mg) was repeatedly fractionated by Sephadex LH-20, using CH~2~Cl~2~--MeOH (1:1) to give a mixture compound (127.6 mg) that was separated using a HPLC column (Hichrome C18, 5 µm, 21.2 mm × 250 mm with 75% MeOH--H~2~O, flowrate 12 mL/min, λ 222 nm) to afford compounds **4** (16.4 mg, at 11.3 min), and **13** (16.1 mg, at 33.5 min). F9 (249.2 mg) was subjected to repeated chromatography on Sephadex LH-20, using CH~2~Cl~2~--MeOH (1:1) to give a mixtures compound (20.3 mg) that was separated using a HPLC column (Hichrome C18, 5 µm, 21.2 mm × 250 mm, with MeOH--H~2~O (45--55% MeOH for 20 min), flowrate 12 mL/min, λ 234 nm) to afford compound **23** (5.4 mg, at 14.7 min). The flesh sponge *Hyrtios erectus* collection CRI 588 (14.0 kg) was cut into small pieces and extracted repeatedly with MeOH (20 L) three times (3 × 20 L). After the evaporation of the solvent, the concentrated MeOH extracts was partitioned between EtOAc and water and the EtOAc fraction was chromatographed on a silica gel column with CH~2~Cl~2~--hexane (1:1) containing increasing proportions of acetone as eluent, to give 7 fractions (A--G). Fraction C (4.0 g) was fractionated by Sephadex LH-20 with MeOH--CH~2~Cl~2~ (1:1) as eluent, to give 2 fractions (C1--C2). C2 (230.3 mg) was repeatedly chromatography on Sephadex LH-20, using CH~2~Cl~2~--MeOH (4:1) to give a mixtures compound (200 mg) that was separated using a HPLC column (Sunfire Prep C18, 5 µm, 10 mm × 250 mm) with MeOH--H~2~O (93:7), flowrate 2.5 mL/min, λ 224 nm, to afford compounds **5** (4.1 mg at 45.5 min), and **6** (7.2 mg at 48.2 min). Fraction D (9.0 g) was further fractionated on a Sephadex LH-20 column chromatography with MeOH--CH~2~Cl~2~ (1:1) to yield 4 fractions (D1--D4). D4 (400 mg) was further purified by HPLC column (Sunfire C18, 5 µm, 19 mm × 250 mm) with CH~3~CN--H~2~O (80:20), flowrate 8 mL/min, λ 224, 236 nm, to afford compounds **1** (5.9 mg, at 23.0 min), **2** (1.6 mg, at 29.6 min), and **3** (7.2 mg, at 35.6 min). Fraction E (25.0 g) was further fractionated by vacuum liquid chromatography eluted with CH~2~Cl~2~--hexane (1:1) containing increasing proportions of acetone as eluent, to give 4 fractions (E1--E4). Fraction E1 (2 g) was further purified by a HPLC column (Sunfire C18, 5 µm, 19 mm × 250 mm) with CH~3~CN--H~2~O (85:15), flowrate 8 mL/min, λ 224, 236 nm, to afford compounds **7** (74 mg, at 32.3 min), **8** (52 mg, at 47.9 min), and **9** (229 mg, 52.8 min). Fraction E3 (3 g) was further purified by a HPLC column (Sunfire C18, 5 µm, 19 mm × 250 mm) with CH~3~CN--H~2~O (80:20), flowrate 8 mL/min, λ 224, 236 nm, to afford compounds **10** (27 mg, at 19.9 min), and **11** (56 mg, at 32.5 min). Fraction E4 (1.4 g) was further purified by HPLC column (Sunfire C18, 5 µm, 19 mm × 250 mm) with CH~3~CN--H~2~O (82:18), flowrate 8 mL/min, λ 224, 236 nm, to afford compounds **13** (72 mg, at 27.35 min) and **14** (33 mg, at 29.3 min). Fraction G (4.0 g) was further filtrated on a Sephadex LH-20 column chromatography with MeOH to give a residue (655 mg), which was further purified by HPLC column (Cosmosil, 5 μ C18-MS-II, 20 mm × 250 mm) with CH~3~CN--H~2~O (60:40), flowrate 8 mL/min, λ 224, 236 nm, to afford compound **12** (70.0 mg, at 64.2 min).

Preparation of (*S*)- and (*R*)-MTPA Esters of compound **3**: To a solution of **3** (3.1 mg) in pyridine (0.9 mL) was added (*R*)-MTPA-chloride (17 µL). The mixture was stirred at room temperature for 3 h, checked with thin layer chromatography (TLC) to make sure that the reaction was complete, quenched by the addition of 2 mL of H~2~O, and the mixture was subsequently extracted with CH~2~Cl~2~ (2 mL) three times (3 × 2 mL). The CH~2~Cl~2~ soluble layers were combined, dried over anhydrous MgSO~4~, and evaporated. The residue was subjected to short silica gel column chromatography using hexane--EtOAc (4:1) to give the (*S*)-MTPA ester **3a** (1.6 mg).

Selected ^1^H NMR (CDCl~3~ 600 MHz) of **3a**: δ~H~ 9.32, s, H-24; 6.28, t (*J* = 7.1 Hz), H-6; 5.86, brs, H-2; 5.79, s, H-25; 5.74, dd (*J* = 7.2, 4.2 Hz), H-4; 5.09, t (*J* = 7.1 Hz), H-10; 3.03, ddd (*J* = 16.1, 6.6, 4.2 Hz), Ha-5; 2.90, dt (*J* = 16.1, 8.0 Hz), Hb-5; 2.24, t (*J* = 7.6 Hz), H~2~-8; 2.02, m, H~2~-9.

The same procedure was used to prepare the (*R*)-MTPA ester **3b** (2.5 mg from 3.9 mg of **3**) with (*S*)-MTPA chloride.

Selected ^1^H NMR (CDCl~3~ 600 MHz) of **3b**: δ~H~ 9.21, s, H-24; 6.13, t (*J* = 7.1 Hz), H-6; 6.00, brs, H-2; 5.81, s, H-25; 5.74, dd (*J* = 7.0, 4.2 Hz), H-4; 5.07, t (*J* = 6.9 Hz), H-10; 3.00, ddd (*J* = 16.2, 6.8, 4.3 Hz), Ha-5; 2.87, dt (*J* = 16.2, 7.5 Hz), Hb-5; 2.20, t (*J* = 7.7 Hz), H~2~-8; 1.99, m, H~2~-9

(*S*)-MTPA esters **5a** (1.3 mg from 1.4 mg of **5**) and **6a** (1.8 mg from 1.4 mg of **6**) and (*R*)-MTPA esters **5b** (1.5 mg from 1.4 mg of **5**), **6b** (1.7 mg from 1.2 mg of **6**) were prepared by the method mentioned above.

Selected ^1^H NMR (CDCl~3~, 400 MHz) of **5a**: δ~H~ 5.77, brs, H-3; 2.72, dd (*J* = 15.7, 6.9 Hz), Ha-1′; 2.62, dd (*J* = 15.7, 3.1 Hz), Hb-1′; 5.28, m, H-2′; 1.67, m, H~2~-3′; 4.56, dd (*J* = 17.8, 1.8 Hz), Ha-5; 4.25, brd (*J* = 17.6 Hz), Hb-5.

Selected ^1^H NMR (CDCl~3~, 400 MHz) of **5b**: δ~H~ 5.86, s, H-3; 2.78, dd (*J* = 15.7, 7.3 Hz), Ha-1′; 2.69, dd (*J* = 15.7, 3.1 Hz), Hb-1′; 5.29, m, H-2′; 1.63, m, H~2~-3′; 4.69, brd (*J* = 17.4 Hz), Ha-5; 4.52, brd (*J* = 17.4 Hz), Hb-5.

Selected ^1^H NMR (CDCl~3~, 600 MHz) of **6a**: δ~H~ 5.77, brs, H-3; 2.72, dd (*J* = 15.6, 7.1 Hz), Ha-1′; 2.63, dd (*J* = 15.6, 3.4 Hz), Hb-1′; 5.28, m, H-2′; 1.71, m, Ha-3′; 1.59, m, Hb-3′; 1.29, m, H~2~-4′; 4.57, dd (*J* = 17.8, 1.6 Hz), Ha-5; 4.26, brd (*J* = 16.7 Hz), Hb-5.

Selected ^1^H NMR (CDCl~3~, 600 MHz) of **6b**: δ~H~ 5.86, brs, H-2; 2.78, dd (*J* = 15.4, 6.58 Hz), Ha-1′; 2.69, dd (*J* = 15.4, 3.6 Hz), Hb-1′; 5.29, m, H-2′; 1.67, m, Ha-3′; 1.55, m, Hb-3′; 1.23, m, H~2~-4′; 4.69, d (*J* = 17.5 Hz), Ha-5; 4.52, d (*J* = 17.5 Hz), Hb-5.

Erectusolide B (**1**): Colorless powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −1.3 (*c* 0.56, CHCl~3~); UV λ~max~ (MeOH) nm (log *ε*) 202 (3.9), 224 (3.4), IR (ATR) *ν*~max~ 3443 (br), 2927, 2861, 1779, 1746, 1629, 1456, 1379, 1266, 1143, 1041, 888, 851, 735, 702 cm^−1^; ^1^H and ^13^C NMR data see [Table 1](#marinedrugs-16-00474-t001){ref-type="table"}; HRAPCIMS *m/z* 385.2727 \[M + H\]^+^ (calcd for C~25~H~37~O~3~, 385.2737).

Erectusolide C (**2**): Colorless powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −18.5 (*c* 0.16, CHCl~3~); UV λ~max~ (MeOH) nm (log *ε*) 234 (4.3); IR (ATR) *ν*~max~ 2924, 2855, 1779, 1748, 1682, 1632, 1458, 1378, 1261, 1142, 1040, 887 cm^−1^; ^1^H and ^13^C NMR data see [Table 1](#marinedrugs-16-00474-t001){ref-type="table"}; HRESIMS *m/z* 405.2390 \[M + Na\]^+^ (calcd for C~25~H~34~NaO~3~, 405.2400).

seco-Manoalide-25-methyl ether (**3**): Pale yellow solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{24}$ −22.2 (*c* 1.86, CHCl~3~); UV λ~max~ (MeOH) nm (log *ε*) 203.5 (4.3), 232 (sh); IR (ATR) *ν*~max~ 3446 (br), 2930, 2863, 1762, 1687, 1457, 1371, 1203, 1120, 1070, 960, 898, 870, 735, 702 cm^−1^; ^1^H and ^13^C NMR data see [Table 2](#marinedrugs-16-00474-t002){ref-type="table"}; HRAPCIMS *m/z* 465.2414 \[M + Cl\]^−^ (calcd for C~26~H~38~ClO~5~, 465.2413).

Erectusolide D (**4**): Pale yellow gum; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −20.9 (*c* 1.64, CHCl~3~); UV λ~max~ (MeOH) nm (log *ε*) 202 (4.3), IR (ATR) *ν*~max~ 3424 (br), 2928, 2857, 1739, 1642, 1456, 1382, 1258, 1172, 1063, 898 cm^−1^; ^1^H and ^13^C NMR data see [Table 2](#marinedrugs-16-00474-t002){ref-type="table"}; HRAPCIMS *m/z* 453.2418 \[M + Cl\]^−^ (calcd for C~25~H~38~ClO~5~, 453.2413).

erectusfuranone A (**5**): Colorless powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +1.3 (*c* 0.32, CHCl~3~); UV λ~max~ (MeOH) nm (log *ε*) 206 (3.9); IR (ATR) *ν*~max~ 3442 (br), 2923, 2853, 1777, 1739, 1637, 1457, 1378, 1175, 1027, 888, 720 cm^−1^; ^1^H and ^13^C NMR data see [Table 3](#marinedrugs-16-00474-t003){ref-type="table"}; HRAPCIMS *m/z* 367.3213 \[M + H\]^+^ (calcd for C~23~H~43~O~3~, 367.3207).

erectusfuranone B (**6**): Colorless powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{26}$ −4.9 (*c* 0.61, CHCl~3~); UV λ~max~ (MeOH) nm (log *ε*) 206 (3.9); IR (ATR) *ν*~max~ 3402 (br), 2916, 2851, 1779, 1756, 1736, 1634, 1469, 1025, 892, 720 cm^−1^; ^1^H and ^13^C NMR data see [Table 3](#marinedrugs-16-00474-t003){ref-type="table"}; HRESIMS *m/z* 353.3053 \[M + H\]^+^ (calcd for C~22~H~41~O~3~, 353.3050).

3.4. Cytotoxicity Assay {#sec3dot4-marinedrugs-16-00474}
-----------------------

Cytotoxic activity for adhesive cell lines including HepG2, HeLa, HuCCA-1, A549, H69AR, KB, T47D, MDA-MB-231, and MRC-5 cell lines were evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay \[[@B25-marinedrugs-16-00474],[@B26-marinedrugs-16-00474]\]. For the non-adhesive MOLT-3 cell line, the cytotoxicity was assessed using the 2,3-bis-(2-methoxy-4-nitro-5-sulphenyl-(2H)-tetrazolium-5-carboxanilide (XTT) assay \[[@B27-marinedrugs-16-00474]\]. Etoposide and doxorubicin were used as positive controls ([Table 4](#marinedrugs-16-00474-t004){ref-type="table"})

4. Conclusions {#sec4-marinedrugs-16-00474}
==============

Two separate collections of *H. erectus* were studied. Three new sesterterpenes, erectusolides B (**1**), C (**2**), and seco-manoalide-25-methyl ether (**3**), two new 2-furanone derivatives, erectusfuranones A (**5**) and B (**6**) together with eight known sesterterpenes, **7**--**14** were isolated from *H. erectus* collection CRI 588. One additional new sesterterpene, erectusolide D (**4**), and ten known compounds (**13**, **15**--**23**) were also obtained from the *H. erectus* collection CRI 572. Three sesterterpenes **8**, **9**, and **20** showed good cytotoxic activity against the MOLT-3 cell line with IC~50~ values of 1.30--7.64 μM and with SI (selectivity index) values 7--9.

The authors thank P. Intachote, S. Sengsai and B. Saimanee for testing cytotoxic activity.

The following are available online at <http://www.mdpi.com/1660-3397/16/12/474/s1>, Figure S1. ^1^H NMR spectrum (600 MHz) of compound **1** in C~6~D~6~, Figure S2.^13^C NMR spectrum (150 MHz) of compound **1** in C~6~D~6~, Figure S3. HSQC spectrum of compound **1** in C~6~D~6~, Figure S4. HMBC spectrum of compound **1** in C~6~D~6~, Figure S5. ^1^H NMR spectrum (600 MHz) of compound **2** in CDCl~3~, Figure S6. ^1^H NMR spectrum (600 MHz) of compound **2** in C~6~D~6~, Figure S7. ^13^C NMR spectrum (150 MHz) of compound **2** in CDCl~3~, Figure S8. ^13^C NMR spectrum (150 MHz) of compound **2** in C~6~D~6~, Figure S9. HSQC spectrum of compound **2** in CDCl~3~, Figure S10. HSQC spectrum of compound **2** in C~6~D~6~, Figure S11. HMBC spectrum of compound **2** in CDCl~3~, Figure S12. HMBC spectrum of compound **2** in C~6~D~6~, Figure S13. ^1^H NMR spectrum (600 MHz) of compound **3** in CDCl~3~, Figure S14. ^13^C NMR spectrum (150 MHz) of compound **3** in CDCl~3~, Figure S15. HSQC spectrum of compound **3** in CDCl~3~, Figure S16. HMBC spectrum of compound **3** in CDCl~3~, Figure S17. ^1^H NMR spectrum (600 MHz) of compound **4** in CDCl~3~, Figure S18. ^13^C NMR spectrum (150 MHz) of compound **4** in CDCl~3~, Figure S19. HMQC spectrum of compound **4** in CDCl~3~, Figure S20. HMBC spectrum of compound **4** in CDCl~3~, Figure S21. ^1^H NMR spectrum (600 MHz) of compound **5** in CDCl~3~, Figure S22. ^13^C NMR spectrum (150 MHz) of compound **5** in CDCl~3~, Figure S23. HSQC spectrum of compound **5** in CDCl~3~, Figure S24. HMBC spectrum of compound **5** in CDCl~3~, Figure S25. ^1^H NMR spectrum (600 MHz) of compound **6** in CDCl~3~, Figure S26. ^13^C NMR spectrum (150 MHz) of compound **6** in CDCl~3~, Figure S27. HSQC spectrum of compound **6** in CDCl~3~, Figure S28. HMBC spectrum of compound **6** in CDCl~3.~

###### 

Click here for additional data file.

Conceptualization, C.M. and S.R.; Funding acquisition, C.M.; Investigation, W.K. and H.P.; Project administration, S.R.; Supervision, S.R.; Validation, H.P.; Writing---original draft, H.P.; Writing---review & editing, P.T. and S.R.

This research received no external funding.

The authors declare no conflict of interest

![Isolated compounds **1**--**23** from sponge *Hyrtios erectus* and luffariolide A.](marinedrugs-16-00474-g001){#marinedrugs-16-00474-f001}

![Key COSY (![](marinedrugs-16-00474-i001.jpg) and ![](marinedrugs-16-00474-i002.jpg)), HMBC (![](marinedrugs-16-00474-i003.jpg)), and NOESY (![](marinedrugs-16-00474-i004.jpg)) correlations of **1**.](marinedrugs-16-00474-g002){#marinedrugs-16-00474-f002}

![Δδ*~S~*~-*R*~ values in ppm for *S*- and *R*-MTPA esters of compound **3** in CDCl~3~.](marinedrugs-16-00474-g003){#marinedrugs-16-00474-f003}

![Key HMBC (![](marinedrugs-16-00474-i005.jpg)), and NOESY (![](marinedrugs-16-00474-i006.jpg)) correlations of **4**.](marinedrugs-16-00474-g004){#marinedrugs-16-00474-f004}

![Key COSY (![](marinedrugs-16-00474-i008.jpg)), long rang COSY (![](marinedrugs-16-00474-i009.jpg)), and HMBC (![](marinedrugs-16-00474-i010.jpg)) correlations of **5**.](marinedrugs-16-00474-g005){#marinedrugs-16-00474-f005}

![Δδ*~S~*~-*R*~ values in ppm for *S*- and *R*-MTPA esters of compounds **5** and **6** in CDCl~3~.](marinedrugs-16-00474-g006){#marinedrugs-16-00474-f006}

marinedrugs-16-00474-t001_Table 1

###### 

^1^H (600 MHz) and ^13^C (150 MHz) NMR data (^a^ in CDCl~3~ ^b^ in C~6~D~6~) of compounds **1** and **2**.

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Position   1                                                                    2                                       
  ---------- --------------- ----------------------- ---------------------------- --------------- ----------------------- ----------------------
  1          174.0 (C)       \-                      \-                           173.3 (C)       \-                      \-

  2          115.3 (CH)      5.86, brd (1.5)         5.66, q (1.6)                116.0 (CH)      5.93, brd (1.6)         5.46, brs

  3          169.7 (C)       \-                      \-                           168.1 (C)       \-                      \-

  4          51.0 (CH)       2.74, d (10.0)          2.24, d (10.1)               50.8 (CH)       2.85, d (9.9)           1.93, d (10.5)

  5          33.3 (CH)       2.85, brt (9.0)         2.60--2.66, m                34.5 (CH)       3.14, brt (8.8)         2.40, brt (10.5)

  6          122.1 (CH)      5.67, brd (0.9)         5.48, brd (1.4)              149.1 (CH)      6.74, t (3.0)           5.85, brt (3.1)

  7          140.9 (C)       \-                      \-                           143.7 (C)       \-                      \-

  8          24.0 (CH~2~)    1.90--2.00, o\          1.76, brt (13.0)\            19.4 (CH~2~)    1.86--1.93, o\          1.51--1.62, o\
                             2.09, dt (16.4, 3.4)    1.90--1.98, o                                2.65, dt (16.8, 3.6)    2.60, dt (13.3, 3.1)

  9          22.8 (CH~2~)    1.65, qd (12.2, 4.2)\   1.42, qd (12.3, 4.1)\        22.3 (CH~2~)    1.50--1.58, o\          0.88--0.96, m\
                             1.82--2.00, o           1.57--1.67, m                                1.88--1.99, o           1.27--1.37, 0

  10         37.0 (CH)       2.25, dt (12.2, 6.9)    2.12, ddd (12.8, 7.9, 6.8)   38.0 (CH)       2.37, dt (11.7, 6.7)    1.82--1.88, o

  11         43.0 (C)        \-                      \-                           43.7 (C)        \-                      \-

  12         36.6 (CH~2~)    1.08--1.20, m\          1.28--1.36, m\               36.6 (CH~2~)    1.15--1.18, o\          1.10--1.17, m\
                             1.49--1.61, o           1.58--1.66, o                                1.55--1.58, o           1.35--1.40, o

  13         22.4 (CH~2~)    1.90--2.00, o           1.94--2.06, o                22.2 (CH~2~)    1.88--1.99, o           1.23--1.40, o\
                                                                                                                          1.78--1.84, o

  14         136.3 (C)       \-                      \-                           136.0 (C)       \-                      \-

  15         127.5 (C)       \-                      \-                           127.7 (C)       \-                      \-

  16         32.7 (CH~2~)    1.89--1.98, o           1.92--2.06, o                32.7 (CH~2~)    1.85--1.99, o           1.78--1.89, o

  17         19.4 (CH~2~)    1.53--1.62, o           1.60--1.68, o                19.4 (CH~2~)    1.52--1.62, o           1.49--1.58, o

  18         39.7 (CH~2~)    1.40--1.44, m           1.49--1.52, m                39.7 (CH~2~)    1.40--1.44, m           1.37--1.42, o

  19         35.1 (C)        \-                      \-                           35.1 (C)        \-                      \-

  20         28.71 (CH~3~)   0.96 \*, s              1.14, s                      28.74 (CH~3~)   0.96, s                 0.99, s

  21         28.72 (CH~3~)   0.97 \*, s              1.11, s                      28.7 (CH~3~)    0.98, s                 1.02, s

  22         19.8 (CH~3~)    1.55, s                 1.66, s                      19.8 (CH~3~)    1.56, s                 1.52, s

  23         21.5 (CH~3~)    1.13, s                 0.88, s                      21.5 (CH~3~)    1.16, s                 0.63, s

  24         66.8 (CH~2~)    4.03, d (13.2)\         3.88, s                      192.9 (CH)      9.45, s                 9.37, s
                             4.06, d (13.2)                                                                               

  25         73.2 (CH~2~)    4.62, dd (17.4, 1.6)\   4.02, dd (17.1, 0.8)\        72.9 (CH~2~)    4.64, dd (17.3, 1.8)\   3.85, dd (17.2)\
                             4.65, dd (17.4, 1.0)    4.16, dd (17.1, 1.7)                         4.68, dd (17.3, 1.1)    4.00, dd (17.2)
  ----------------------------------------------------------------------------------------------------------------------------------------------

\* Interchangeable; o = overlapped signals; Assignments are based on COSY, HSQC ([Figures S3, S9 and S10](#app1-marinedrugs-16-00474){ref-type="app"}), and HMBC experiments.

marinedrugs-16-00474-t002_Table 2

###### 

^1^H (600 MHz) and ^13^C (150 MHz) NMR data (CDCl~3~) of compounds **3** and **4**.

  ----------------------------------------------------------------------------------------------------
  Position   3              4                                            
  ---------- -------------- ---------------------------- --------------- -----------------------------
  1          169.2 (C)      \-                           172.7 (C)       \-

  2          119.3 (CH)     6.09, brt (1.3)              116.0 (CH)      6.04, brd (1.4)

  3          166.3 (C)      \-                           171.7 (C)       \-

  4          66.9 (CH)      4.73, brdd (6.7, 4.1)        81.8 (CH)       5.08, m

  5          34.7 (CH~2~)   2.78, dt (15.7, 7.5)\        30.2 (CH~2~)    2.57, ddd (15.0, 7.3, 5.5)\
                            2.92, ddd (15.7, 7.1, 4.1)                   2.78, dt (15.0, 7.0)

  6          147.0 (CH)     6.54, t (7.1)                119.9 (CH)      5.19, t (7.5)

  7          146.1 (C)      \-                           143.0 (C)       \-

  8          24.6 (CH~2~)   2.32, t (7.4)                35.4 (CH~2~)    2.10--2.22, m

  9          26.7 (CH~2~)   2.09, q (7.4)                26.3 (CH~2~)    2.07--2.17, m

  10         122.4 (CH)     5.13, td (7.3, 1.0)          123.6 (CH)      5.07, m

  11         137.5 (C)      \-                           136.6 (C)       

  12         40.2 (CH~2~)   1.95--2.07, m                33.7 (CH~2~)    1.68, td (13.5, 3.5)\
                                                                         1.86--1.96, m

  13         27.8 (CH~2~)   1.97--2.07, m                31.0 (CH~2~)    1.49--1.60, m\
                                                                         1.88, td (11.7, 4.3)

  14         137.0 (C)      \-                           80.4 (C)        \-

  15         127.0 (C)      \-                           150.5 (C)       \-

  16         32.8 (CH~2~)   1.90, t (6.2)                34.0 (CH~2~)    1.97, td (13.0, 5.7)\
                                                                         2.32, brd (13.0)

  17         19.5 (CH~2~)   1.54--1.59, m                22.7 (CH~2~)    1.43--1.65, m

  18         39.9 (CH~2~)   1.39--1.43, m                38.0 (CH~2~)    1.37, brd (13.7)\
                                                                         1.63, td (13.7, 4.5)

  19         35.0 (C)       \-                           39.7 (C)        \-

  20         28.6 (CH~3~)   0.99, s                      24.1 (CH~3~)    0.96, s

  21         28.6 (CH~3~)   0.99, s                      22.1 (CH~3~)    0.88, s

  22         19.8 (CH~3~)   1.59, s                      108.3 (CH~2~)   4.83, brs\
                                                                         4.91, brs

  23         16.0 (CH~3~)   1.61, s                      16.3 (CH~3~)    1.60, s

  24         194.2 (CH)     9.43, s                      60.3 (CH~2~)    4.10, d (12.1)\
                                                                         4.13, d (12.1)

  25         103.3 (CH)     5.84, s                      58.6 (CH~2~)    4.44, d (16.9)\
                                                                         4.52, d (16.9)

  OMe-25     57.9 (CH~3~)   3.65, s                                      
  ----------------------------------------------------------------------------------------------------

Assignments are based on COSY, HSQC ([Figure S15](#app1-marinedrugs-16-00474){ref-type="app"}) or HMQC ([Figure S19](#app1-marinedrugs-16-00474){ref-type="app"}), and HMBC experiments.

marinedrugs-16-00474-t003_Table 3

###### 

^1^H (600 MHz) and ^13^C (150 MHz) NMR data (CDCl~3~) of compounds **5** and **6**.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Position   5                                                            6                                                                                                                           
  ---------- ------------------------------------ ----------------------- --------------- ------------------------------------ ---------------------------------------------------------------------- ---------------
  2          173.8 (C)                            \-                      173.9 (C)       \-                                                                                                          

  3          117.3 (CH)                           5.93, s                 117.2 (CH)      5.93, s                                                                                                     

  4          167.3 (C)                            \-                      167.4 (C)       \-                                                                                                          

  5          73.8 (CH~2~)                         4.85, s                 73.8 (CH~2~)    4.85, s                                                                                                     

  1′         36.3 (CH~2~)                         2.52, dd (14.8, 8.2)\   36.5 (CH~2~)    2.52, dd (15.2, 8.2)\                                                                                       
                                                  2.64, dd (14.8, 3.2)                    2.64, dd (15.2, 3.4)                                                                                        

  2′         70.2 (CH)                            3.84--3.90, m           70.2 (CH)       3.84--3.89, m                                                                                               

  3′         37.7 (CH~2~)                         1.49--1.54, m           37.7 (CH~2~)    1.49--1.55, m                                                                                               

  4′         25.5 (CH~2~)                         1.28--1.38, m\          25.5 (CH~2~)    1.30--1.47, m                                                                                               
                                                  1.39--1.46, m                                                                                                                                       

             ![](marinedrugs-16-00474-i007.jpg)   (CH~2~)-5′--\           1.22--1.50, m   ![](marinedrugs-16-00474-i007.jpg)   (CH~2~)-5′--\                                                          1.22--1.38, m
                                                  (CH~2~)-14′\                                                                 (CH~2~)-14′\                                                           
                                                  30.0, 29.68,\                                                                29.65, 29.65, 29.65, 29.63, 29.61, 29.61, 29.58, 29.50, 29.50, 29.42   
                                                  29.64, 29.63,\                                                                                                                                      
                                                  29.61, 29.57,\                                                                                                                                      
                                                  29.49, 29.49,\                                                                                                                                      
                                                  29.48,\                                                                                                                                             
                                                  27.1 (C-14′)                                                                                                                                        

  15′        36.6 (CH~2~)                         1.07--1.17, m\          29.3 (CH~2~)    1.22--1.38, m                                                                                               
                                                  1.23--1.37, m                                                                                                                                       

  16′        34.4 (CH)                            1.23--1.37, m           31.9 (CH~2~)    1.22--1.31, m                                                                                               

  17′        29.42 (CH~2~)                        1.22--1.50, m           22.6 (CH~2~)    1.22--1.38, m                                                                                               

  18′        11.3 (CH~3~)                         0.85, t (7.2)           14.0 (CH~3~)    0.88, t (7.0)                                                                                               

  19′        19.2 (CH~3~)                         0.84, d (6.0)           \-              \-                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Assignments are based on COSY, HSQC ([Figures S23 and S27](#app1-marinedrugs-16-00474){ref-type="app"}), and HMBC ([Figures S24 and S28](#app1-marinedrugs-16-00474){ref-type="app"}) experiments.
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###### 

Cytotoxicity of compounds **3**, **5**, **7**--**20** and **23** (IC~50~, μM).

  Compound      MOLT-3        HepG2         HeLa          HuCCA-1       A549          H69AR    KB            T47D     MDA-MB-231    MRC-5
  ------------- ------------- ------------- ------------- ------------- ------------- -------- ------------- -------- ------------- -------------
  **3**         15.84         27.91         20.02         24.72         41.12         \- ^a^   \- ^a^        \- ^a^   40.09         \- ^a^
  **5**         31.75         107.46        28.79         65.57         57.24         \- ^a^   \- ^a^        \- ^a^   89.26         \- ^a^
  **7**         40.11         I             87.95         I             I             \- ^a^   \- ^a^        \- ^a^   I             \- ^a^
  **8**         1.77          53.49         8.42          11.02         16.77         \- ^a^   \- ^a^        \- ^a^   39.53         13.00
  **9**         1.30          27.91         1.51          8.60          12.00         \- ^a^   \- ^a^        \- ^a^   18.60         10.84
  **10**        35.45         I             78.71         I             I             \- ^a^   \- ^a^        \- ^a^   I             \- ^a^
  **11**        17.38         I             87.04         84.52         I             \- ^a^   \- ^a^        \- ^a^   I             \- ^a^
  **12**        37.81         I             79.20         119.35        I             \- ^a^   \- ^a^        \- ^a^   I             \- ^a^
  **13**        34.10         88.73         59.30         94.65         114.30        \- ^a^   \- ^a^        \- ^a^   92.04         \- ^a^
  **14**        6.68          101.75        21.80         47.38         58.13         \- ^a^   \- ^a^        \- ^a^   84.13         17.48
  **15**        \- ^a^        \- ^a^        63.08         49.07         \- ^a^        51.40    58.41         28.04    14.02         \- ^a^
  **16**        124.32        I             77.54         I             I             \- ^a^   \- ^a^        \- ^a^   I             \- ^a^
  **17**        \- ^a^        \- ^a^        63.08         60.75         \- ^a^        107.48   63.08         42.06    60.75         \- ^a^
  **18**        \- ^a^        \- ^a^        23.32         41.45         \- ^a^        56.99    6.99          5.18     5.96          \- ^a^
  **19**        13.83         75.45         65.32         60.81         60.81         \- ^a^   \- ^a^        \- ^a^   \- ^a^        \- ^a^
  **20**        7.64          27.36         \- ^a^        87.06         73.38         \- ^a^   \- ^a^        \- ^a^   \- ^a^        70.97
  **23**        77.98         I             I             I             I             \- ^a^   \- ^a^        \- ^a^   \- ^a^        \- ^a^
  Doxorubicin   \- ^a^        0.36 ± 0.05   0.19 ± 0.00   0.40 ± 0.03   0.35 ± 0.02            1.64 ± 0.15            1.64 ± 0.17   3.16 ± 0.10
  Etoposide     0.04 ± 0.01   \- ^a^        \- ^a^        \- ^a^        \- ^a^                 \- ^a^                 \- ^a^        \- ^a^

I = inactive at IC~50~ \> 50 µg/mL; ^a^ not determined; etoposide and doxorubicin were used as the reference compounds.
